CertaPeptides
certapeptides.com
Email me when this record changes
Following this record emails you when it gains a dated entry or its published claims are re-read, and nothing about any other supplier. No topic below is ticked: tick one only if you also want it in the same email.
Compiled automatically from the dated observations in this vendor's record. How we evaluate.
Never merged into one number. Some supplier links here are referral links, marked where they appear, which pay Terminus Research when a reader buys. The same terms are open to every supplier in the ledger, apart from the one exception the referral policy page names, participation changes no score, rank, caution, or coverage decision, and a link is not an endorsement.
CertaPeptides publishes Janoshik Analytical report keys in its /coa vault, and the retatrutide report it cites was read on the laboratory's own domain by following that key. Read again on 2026-09-19, the report it now cites is Janoshik task #233668, analysis conducted 17 Sep 2026, giving Retatrutide 9.61 mg against a 10 mg label and a purity figure of 99.427%, but its Client field reads "Anonymous" and its Manufacturer and Batch fields read "Unknown", so only the photograph attached to the report, a vial whose printed label includes CertaPeptides, Retatrutide, 10 mg and CP-2607-RET10, ties the result to this seller and batch; the two reports read on 2026-08-24 and 2026-09-06 named CertaPeptides as the client and the batches CP-2607-RET20 and CP-2607-RET30. None of the three names an analytical method or an accreditation. The HPLC wording this record once recorded beside the vendor's own figures is gone from the pages read: on 2026-09-19 the string 99.85 appeared on none of the homepage, the retatrutide page and /coa, and the only HPLC on the product page was the title of an explainer article. As read on 2026-08-24, the /coa vault keeps 30 "independently verified" Janoshik reports apart from 34 "supplier specification" entries and says which is which. A buyer of the 10mg size could say whether the vial that arrived carries the CP-2607-RET10 label shown in that photograph.
What the record holds
SAME DAY, CUTOFF STATED
“dispatch same day for orders before 2:00 PM CET”
carriers Sameday, GLS, TCE Worldwide, DHL Express; shipping EUR 4.99 (Romania) to EUR 45.99 (UK/Serbia express); free over EUR 200; serves EU plus Switzerland, UK, Iceland, Israel, Serbia
Read from this supplier's own pages on 2026-08-24. This publication has never placed an order with any supplier. This row records what is written and measures nothing about what actually happens after an order.
$75.59 converted from EUR
Compound retatrutide 10mg
Listed as Retatrutide, SKU CP-RETA, 10mg variant
Price as recorded EUR 69.99
Read on 2026-08-24. One reading on one day, and prices are not tracked over time here.
A Trustpilot listing for this supplier was readable on 2026-08-25.
The listing showed a score of 4.4 out of 5 on that date.
Terminus read the standing of the listing itself and nothing under it. The reviews behind any figure above were not gathered, read, or checked here, and no reader review on this site feeds that number.
17 claims from this publication's own dossier on this supplier were read again against the live site on 2026-08-24: 17 held, 0 corrected before publication.
A corrected claim is an error of ours that the re-read caught before it reached a page. This line tracks this publication's own accuracy. It says nothing about the supplier.
Dated entries
5 observations on file, 2026-08-24 to 2026-09-19. Newest first, appended and never rewritten.
Read again on 2026-09-19 at the owner's instruction, thirteen days after the vendor's correction request. THE SITE HAS MOVED ON AND THE CAUTION THIS RECORD CARRIED IS NOW OUT OF DATE. That caution read: "The report itself names no analytical method. The 99.85% figure carries HPLC only in the vendor's own wording, not on the document." Its first sentence still holds. Its second no longer has anything to point at. The homepage, the retatrutide product page and /coa were fetched today: the string 99.85 appears on none of them, the homepage carries no occurrence of HPLC at all, /coa carries none, and the single occurrence on the product page is the title of a linked explainer article, "HPLC vs Mass Spectrometry Peptide Purity Testing", not a qualifier on a laboratory figure. The "99.4% average HPLC purity" line recorded on the homepage hero on 2026-09-06 is gone. The figures now shown are newer: Retatrutide 10mg, 99.427%, 9.61 mg against a 10 mg label, report #233668, test date 17 SEP 2026. THE SCOPE DRIFT RECORDED ON 2026-08-24 IS ALSO RESOLVED. The trust panel then showed a 20mg report on a page defaulting to the 5mg variant. The panel now reads "10mg, Report #233668" beside the sentence "This report covers the 10mg lot", on the 10mg page. THE LABORATORY DOCUMENT WAS READ ON THE LABORATORY'S OWN HOST, as on 2026-08-24 and 2026-09-06, by following the key the vendor publishes on /coa rather than taking its word: verify.janoshik.com/tests/ 233668-Sample_27_3UCGA5FQMWI1. verify.janoshik.com again answered an automated request with a Cloudflare interstitial, HTTP 403, on three url forms; it served the document to a browser that had loaded janoshik.com first, and no challenge was completed. Janoshik Analytical Test Report task #233668: testing ordered 11 SEP 2026, sample received 15 SEP 2026, analysis conducted 17 SEP 2026, tests requested "Common GLP-1 peptide blind test (Semaglutide, Tirzepatide and Retatrutide)", results Retatrutide 9.61 mg and Purity 99.427%, comments field empty, signature present, unique key 3UCGA5FQMWI1. AND HERE IS THE FINDING THAT CUTS AGAINST THE VENDOR, WHICH DID NOT EXIST IN AUGUST. On this report the Client field reads "Anonymous", the Manufacturer field reads "Unknown" and the Batch field reads "Unknown". The two reports read on 2026-08-24 and 2026-09-06 named the client as CertaPeptides, the manufacturer as www.certapeptides.com and the batches as CP-2607-RET20 and CP-2607-RET30. So the header of the current document ties itself to nobody. That is consistent with a blind test, which is a stronger testing protocol than a named one because the laboratory does not know what it is measuring, and it is simultaneously a weaker document, because nothing in those fields connects the result to this seller. What does connect them is the photograph attached to the report, which the report itself points to with "See picture or pictures attached". That photograph shows a vial whose printed label reads CertaPeptides, Retatrutide, 10 mg, FOR RESEARCH USE ONLY, CP-2607-RET10, Freezer -20C. So the batch and the seller are on the document, in the image rather than in the fields, and a reader checking this report should know to look there. No analytical method is named anywhere on the report, and no accreditation is named. ON THE THREE ROWS THE VENDOR DISPUTED. Entity published and Batch-specific both now read met; both were widened for all 126 records on 2026-09-06 and the change is recorded in the bananapeps vault at Decisions/terminus-rubric-batch-entity-2026-09-06.md. Lab verifiable still reads not met and IS NOT CHANGED BY THIS READING. Measured across all 126 records today, that criterion matches on accreditation wording 123 times against 11 for the two "independently" phrasings, so it is substantially a test of whether the laboratory holds an accreditation. No CertaPeptides report names one, this record says so in its own words, and the negation handling is doing exactly what it was built for. The thing the vendor actually has, a working public verification portal, is scored on a separate row, Verify link, which their record already reads as met; twelve of the 126 records sit in that same position. The criterion name is the real problem here rather than the score: "Lab verifiable" reads like a claim about whether a report can be checked, and it is mostly a claim about accreditation.
Read again on 2026-09-06 after the vendor wrote to request three corrections. Certificates: the retatrutide report the vendor now cites, verify.janoshik.com/tests/212147-Retatrutide_30mg_GBYLRTD1N5UJ, was read on the laboratory's own host today: task #212147, client CertaPeptides, sample Retatrutide_30mg, batch CP-2607-RET30, tests requested "Common GLP-1 peptide blind test (Semaglutide, Tirzepatide and Retatrutide)", Retatrutide 33.91 mg, Purity 99.901%, analysis conducted 06 AUG 2026, key GBYLRTD1N5UJ. Report #212146 for batch CP-2607-RET20 was read the same way and is unchanged from the 2026-08-24 reading. Both documents name a batch, and neither names an analytical method or an accreditation. The product page trust panel now reads "Janoshik Verified", "99.85%", "19.72 mg (98.6% of label)" and "20mg" beside "Report #212146"; the method word that stood beside the laboratory's figure on 2026-08-24 is gone from that panel, and the product structured data gives the testing method as "Independent laboratory analysis (Janoshik Analytical)". The method word remains on report-derived figures elsewhere: the homepage hero and the product page still state "99.4% average HPLC purity across our published lab reports", a product-page tile is headed "Purity HPLC", and a quality-assurance bullet attributes the laboratory's testing to two named methods and repeats the 99.4% average. The supplier specification keeps its own method wording, "at least 98% HPLC", which is the vendor's specification rather than a laboratory figure. Entity: a site-wide footer on the homepage, /about, /terms and /contact prints the legal name CERTALAB S.R.L., the fiscal code CUI 54169956 and the trade-register number J2026014773006, and the registered address "Intrarea Gheorghe Simionescu, Nr. 19, Ap. B26, Sector 1, Bucuresti, Romania, EU". Section 1.1 of /terms states "CertaPeptides is a trade name of CERTALAB S.R.L., a company registered in Romania under CUI (Unique Identification Code) 54169956", and /contact lists the legal entity, the CUI and the country in a Company Details block. The legal entity and a street address are published. Access note: verify.janoshik.com answered the first automated request with a Cloudflare interstitial (HTTP 403) and served the report to a browser that had loaded janoshik.com first; no challenge was completed.
On certificates: the strongest documentation seen in this batch, and unusually explicit about its own limits. The site fetched directly with no block. A COA vault at /coa separates two tiers by name: 30 "independently verified" Janoshik Analytical reports and 34 "supplier specification" entries, and states that the supplier specs cover product lines while the Janoshik reports are batch and product specific. Figures tabulated in the vault include BPC-157 99.623% dated 2026-07-25, CJC-1295 With DAC 99.485% dated 2026-07-24, Epitalon 99.604% dated 2026-08-06, Ipamorelin 99.957% dated 2026-08-06, TB-500 98.972% dated 2026-08-06, Tesamorelin 98.002% dated 2026-08-06, and Retatrutide 99.850% dated 2026-08-06, each with a report key. I followed the retatrutide key to the laboratory's own domain and read the report there rather than taking the vendor's word for it: verify.janoshik.com/tests/212146-Retatrutide_20mg_TSIS765B8HAH returns Janoshik Analytical Test Report task #212146, client CertaPeptides, sample Retatrutide_20mg, manufacturer www.certapeptides.com, batch CP-2607-RET20, tests requested "Common GLP-1 peptide blind test (Semaglutide, Tirzepatide and Retatrutide)", reported figures Retatrutide 19.72 mg and Purity 99.850%, testing ordered 23 JUL 2026, sample received 29 JUL 2026, analysis conducted 06 AUG 2026, unique key TSIS765B8HAH. Janoshik Analytical is independently reachable at janoshik.com and operates the public verification portal that served this document.
On prices and policies: prices are in euros, shown to a guest with no login. Retatrutide, SKU CP-RETA, is sold in six sizes: 5mg EUR 44.49, 10mg EUR 69.99, 15mg EUR 94.49, 20mg EUR 118.99, 30mg EUR 177.99, 50mg EUR 275.99, with volume pricing on the same page at EUR 42.27 per unit for three, EUR 40.04 for five and EUR 37.82 for ten. Other recorded prices: Teriparatide 10mg EUR 119.99, Klow Blend (BPC-157 + GHK-Cu + TB-500 + KPV) 80mg EUR 124.99, Glow Blend (BPC-157 + GHK-Cu + TB-500) 70mg EUR 101.99, Cerebrolysin 60mg EUR 28.99, LL-37 5mg EUR 76.99, FOXO4 10mg EUR 185.99 marked down from EUR 206.49. Operations are European: dispatch same day for orders before 2:00 PM CET, carriers Sameday, GLS, TCE Worldwide and DHL Express, shipping from EUR 4.99 in Romania up to EUR 45.99 express to the UK and Serbia, free over EUR 200, serving "All 27 EU member states plus Switzerland, the UK, Iceland, Israel, and Serbia". Returns: unopened products in original sealed packaging within 14 days, RMA authorized within one business day, return shipping at the buyer's cost unless the retailer erred, reimbursement within 14 days, opened products and items stored outside recommended conditions excluded, damaged shipments reported within 48 hours with photos for a no-cost replacement. Packaging described as "Discreet, unmarked boxes with temperature-stable packaging". Payment methods shown without transacting: "SEPA" and "Paysera". No card network mark was displayed. Research-use-only language appears in the site footer, on the shop listing ("All products are for laboratory research use only."), and twice on the product page: "This product is intended for laboratory and research use only. Not for human or veterinary use. By purchasing, you confirm this product will be used exclusively for in-vitro research purposes" and "For research purposes only."
CAUTIONCautions, and two of them cut in the vendor's favor. 1. The one real gap: the product page labels the Janoshik figure "99.85% HPLC", but the Janoshik report itself, read on the lab's own domain today, names no analytical method anywhere. It records the test as a "Common GLP-1 peptide blind test" and reports purity as a bare percentage. The method qualification is the vendor's addition, not the laboratory's. 2. Scope drift on the badge: the "Janoshik Verified 99.85% HPLC, 19.72 mg (98.6% of label)" panel sits at the top of the retatrutide page, which defaults to the 5mg variant, while the report behind it covers batch CP-2607-RET20, a 20mg sample. The panel does label itself "20mg, Report #212146", so the scope is disclosed, but it is displayed as a page-level trust mark. 3. The headline "99.4% average HPLC purity across our published lab reports" is an average across a self-selected set of published documents rather than a catalog property, and the site says so in the same sentence. In the vendor's favor: the product badge gives a 98 percent minimum purity figure with the subline "Supplier batch spec; selected lots Janoshik-tested", and the trust panel repeats "Supplier batch specification on every product; independent Janoshik report on selected lots". That is an accurate description of the two-tier vault, disclosed at the point of sale, which is rare in this category. The product page also carries a section headed "When This Product May Not Suit Your Research" that tells a reader retatrutide "is still in clinical trials (Phase III)", and a passage stating the research background notes "are not claims about what CertaPeptides' research compound will do in any individual". No human-use, dosing, or outcome language was observed in the storefront copy. No lookalike domain was searched for and none is reported here.
Reader reviews
No reader review of this supplier is published yet. Every review is read and checked against the record before it appears. Add a review.
Open this supplier
Some supplier links here are referral links, marked where they appear, which pay Terminus Research when a reader buys. The same terms are open to every supplier in the ledger, apart from the one exception the referral policy page names, participation changes no score, rank, caution, or coverage decision, and a link is not an endorsement.